Clinical trial
Safety and Efficacy of Escalating Doses of LEO 43204 Applied Once Daily for Two Consecutive Days on Full Balding Scalp in Subjects With Actinic Keratosis
NCT02100813 is registered in ClinicalTrials.gov with LEO Pharma as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Safety and Efficacy of Escalating Doses of LEO 43204 Applied Once Daily for Two Consecutive Days on Full Balding Scalp in Subjects With Actinic Keratosis
- Lead sponsor
- LEO Pharma
- Phase
- Phase 1/2
- Overall status
- Completed
- Start date
- May 31, 2014
- Completion date
- March 31, 2015
- Enrollment
- 220 (actual)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.
actinic keratosis